AstraZeneca Covid shot 'less effective against South African variant'

Study shows little effect on patients with mild to moderate coronavirus symptoms

A study has shown that the AstraZeneca Covid-19 vaccine is less effective in fighting the the South African variant. AFP.

British drugmaker AstraZeneca said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of Covid-19, based on early data from a trial.

The study from South Africa's University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report.

Among coronavirus variants currently most concerning for scientists and public health experts are the so-called British, South African and Brazilian variants, which appear to spread more swiftly than others.

• 

  People are seen around Perth, Australia. Western Australia's Covid-19 lockdown restrictions were lifted at 6pm on Friday after no new community coronavirus cases were recorded in the last week. Getty Images

• 

  Portuguese Prime Minister António Costa addresses journalists at the end of a visit to a hospital where health care workers were being vaccinated against Covid-19, in Lisbon, Portugal. AP

• 

  Theatre creator Silas Rayner continues with construction work on the "Thorington Theatre in the Woods", a 350 seat capacity performance space, designed by festival business owner Rayner, which is made with local coppiced wood in order to be truly sustainable and set in a natural woodland amphitheatre in Lindy O'Hare's farm estate, amid the spread of the coronavirus disease (COVID-19), near Southwold, Britain. Reuters

• 

  Members of the World Health Organisation team tasked with investigating the origins of Covid-19 walk down a corridor after meetings with the Chinese side in the cordoned wing of their hotel in Wuhan in central China's Hubei province. AP Photo

• 

  Dominic Dwyer, a member of the World Health Organisation team tasked with investigating the origins of Covid-19, walks at a hotel in Wuhan, Hubei province, China. Reuters

• 

  A staff member wearing a face maskis reflected in the goggles of a skier at the National Alpine Skiing Center in Yanqing on the outskirts of Beijing. Beijing Olympic organisers showed off the downhill skiing venue and the world's longest bobsled and luge track Friday, one year ahead of the scheduled opening of the 2022 Olympic Winter Games. AP Photo

• 

  A worker welds and seals the aluminum lid of the coffin with a Covid-19 victim in Penafiel, Portugal. Getty Images

• 

  A Kansas City Chiefs fan wears a themed face mask ahead of the weekend's Super Bowl LV between the Kansas City Chiefs and Tampa Bay Buccaneers in Tampa, Florida, US. Reuters

• 

  Healthcare workers treat a Covid-19 patient in a Step Down Unit at Providence Holy Cross Medical Center in Mission Hills, California, US. Bloomberg

• 

  Immigrants participate in a socially-distanced outdoor naturalisation ceremony to become new US citizens, as the coronavirus outbreak continues, in Los Angeles, California. Reuters

• 

  Healthcare workers administer Pfizer-BioNTech Covid-19 vaccines at a vaccination site inside a church in the Bronx borough of New York, US. Bloomberg

• 

  Buddhist monks wear face masks as they receive alms from devotees in Phnom Penh, Cambodia. AP Photo

• 

  Workers leave after burying a victim of coronavirus at a Muslim cemetery in Gombak, outskirts of Kuala Lumpur, Malaysia. AP Photo

• 

  People wearing face masks rest at Hinokicho Park in Tokyo. AP Photo

• 

  Women wearing face masks as a precaution against the coronavirus ride on a scooter past boats displayed for sale by a roadside in Alappuzha, Kerala state, India. AP Photo

• 

  Beneficiaries wait for their turn to get her first dose of a Covid-19 vaccine shot, manufactured by Serum Institute of India, inside Vaccination Centre at Shatabdi Hospital in Mumbai, India. EPA

"In this small phase I/II trial, early data has shown limited efficacy against mild disease primarily due to the B. 1.351 South African variant," an AstraZeneca spokesman said.

"However, we have not been able to properly ascertain its effect against severe disease and hospitalisation given that subjects were predominantly young healthy adults."

The company said it believed its vaccine could protect against severe disease, given that the neutralising antibody activity was equivalent to that of other Covid-19 vaccines.

While thousands of individual changes have arisen as the virus mutates into new variants, only a tiny minority are likely to be important or change the virus in an appreciable way, according to the British Medical Journal.

"Oxford University and AstraZeneca have started adapting the vaccine against this variant and will advance rapidly through clinical development so that it is ready for Autumn delivery should it be needed," the AstraZeneca spokesman said.

The trial involving more than 2,000 people has not been peer-reviewed, the FT said.

On Friday Oxford said their vaccine has similar efficacy against the British coronavirus variant as it does to the previously circulating variants.